|

Elevated Rate Pacing of Cardiac Amyloidosis

RECRUITINGN/ASponsored by University of Minnesota
Actively Recruiting
PhaseN/A
SponsorUniversity of Minnesota
Started2025-10-10
Est. completion2026-10-10
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07583823

Summary

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults 18 and older
* Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
* Implanted Cardiac Pacemaker (+/- Defibrillator)
* Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation
* Non-dilated left ventricle by echocardiography
* Ability to provide written consent
* English Speaking

Exclusion Criteria:

* Paced QRS duration of \>150 ms (indicator for pacing mediated dyssynchrony)
* Dilated left ventricle

Conditions3

Cardiac AmyloidosisHeart DiseasePacemaker

Locations1 site

University of Minnesota
Minneapolis, Minnesota, 55455
Meghan Muscala612-626-5863payne324@umn.edu

Find trials near these locations

Heart Disease trials in MinneapolisAll trials in Minnesota

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.